Table 1.
Characteristics of pediatric liver transplant recipient cohort (n=70)
| Gender | |
| Female | 43% |
| Male | 57% |
| Age at Transplant | |
| < 1 year | 57% |
| 1–2 years | 21% |
| 2–5 years | 21% |
| Race | |
| Caucasian | 39% |
| African-American | 4% |
| Asian | 23% |
| Other/Unknown | 34% |
| Ethnicity | |
| Latino | 31% |
| Diagnosis category* | |
| Biliary atresia | 46% |
| Metabolic disease | 21% |
| Cholestatic conditions | 13% |
| Acute liver failure | 11% |
| Tumor | 6% |
| Other | 3% |
| Donor Type | |
| Deceased-donor | 69% |
| Living-related | 31% |
| Organ transplant type | |
| Whole liver | 34% |
| Split liver (deceased donor) | 34% |
| Partial liver (living-related) | 31% |
| Ascites at transplant | |
| Yes, on exam | 33% |
| Yes, on imaging | 1% |
| No | 11% |
| Not recorded | 17% |
| Unknown | 37% |
| On diuretics at discharge from transplant admission | |
| Yes | 31% |
| No | 66% |
*
Metabolic liver disease includes alpha-1-antitrypsin deficiency, Crigler-Najjar syndrome, cystic fibrosis, glycogen storage disease, inborn errors in bile acid metabolism, neonatal hemochromatosis, primary hyperoxaluria, tyrosinemia, urea cycle defects, Wilson’s disease. Cholestatic conditions include Alagille syndrome, Byler disease, progressive intrahepatic cholestatic syndromes, total parenteral nutrition cholestasis, sclerosing cholangitis, and idiopathic cholestasis. Other liver disease includes congenital hepatic fibrosis, Budd-Chiari syndrome, autoimmune hepatitis cirrhosis, drug toxicity, hepatitis C cirrhosis, and unknown cirrhosis.